Feb 06, 2019 / 02:00PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Eli Lilly Fourth Quarter 2018 Earnings Call. (Operator Instructions) As a reminder, today's call is being recorded. I'll turn the conference now to Mr. Kevin Hern, Vice President of Investor Relations. Please go ahead, sir.
Kevin Hern - Eli Lilly and Company - VP of IR
Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2018 earnings call. I'm Kevin Hern, Vice President of Investor Relations. Joining me on today's call are: Dave Ricks, Lilly's Chairman and CEO; Josh Smiley, our Chief Financial Officer; Dr. Dan Skovronsky, President of Lilly Research Laboratories; Christi Shaw, President of Lilly Bio-Medicines; Anne White, President of Lilly Oncology; and Enrique Conterno, President of Lilly Diabetes and Lilly U.S.A. We're also joined by Kim Macko and Mike Czapar of the Investor Relations team.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to
Q4 2018 Eli Lilly and Co Earnings Call Transcript
Feb 06, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers